Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 5/20 | 0.61 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | SYK | P43405 | 2/20 | 0.50 |
| ▸ | AURKA | O14965 | 1/20 | 0.50 |
| ▸ | IGF1R | P08069 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | CDK1 | P06493 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30394764 | 0.85 | EGFR (0.64) | EGFRNFKB1AURKAPOLBHTT | |
| SCHEMBL9945499 | 0.85 | EGFR (0.64) | EGFRNFKB1SYKAURKAPOLB | |
| SCHEMBL9945497 | 0.85 | EGFR (0.64) | EGFRNFKB1AURKAPOLBHTT | |
| SCHEMBL4175837 | 0.84 | SYK (0.51) | EGFRMEN1KMT2ASYKIGF1R | |
| SCHEMBL655633 | 0.83 | SYK (0.72) | EGFRMEN1KMT2ASYKIGF1R | |
| SCHEMBL19958510 | 0.83 | EGFR (0.61) | EGFRNFKB1SYKAURKAPOLB | |
| SCHEMBL12518356 | 0.83 | AURKA (0.72) | EGFRNFKB1SYKAURKAIGF1R | |
| SCHEMBL13606356 | 0.83 | EGFR (0.61) | EGFRNFKB1SYKAURKAPOLB | |
| SCHEMBL29860412 | 0.82 | MEN1 (0.56) | EGFRMEN1KMT2ASYKIGF1R | |
| SCHEMBL27047622 | 0.82 | MEN1 (0.56) | EGFRMEN1KMT2ASYKIGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149687-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149687-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | ABCG2, CYP3A5, CYP3A43 | EGFR 2849/4885NFKB1 2968/4885MEN1 243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.